NCT00030901

S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate

L-Selenium-Based Chemoprevention Of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 619 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: Male
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of selenium may be an effective way to prevent prostate cancer in patients who have neoplasia of the prostate. PURPOSE: Randomized phase III trial to study the effectiveness of selenium in preventing prostate cancer in patients who have neoplasia of the prostate.

Detailed description

OBJECTIVES: * Compare the effects of selenium versus placebo on the 3-year incidence rate of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. * Compare the toxicity of these regimens in these patients. * Compare the effects of these regimens on the rate of increase in prostate-specific antigen (PSA) in these patients. * Compare the effects of these regimens on prostatic cellular proliferation and apoptosis, degradation of basal cell integrity of prostatic ducts, and changes in nuclear chromatin patterns in these patients. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to age (40-60 vs 61 and over), race (African American vs other), baseline PSA (less than 4 ng/mL vs 4-10 ng/mL), concurrent vitamin E supplementation (yes vs no), and cores obtained from initial biopsy (10 or more vs less than 10). Patients are randomized to 1 of 2 arms. * Arm I: Patients receive oral selenium once daily. * Arm II: Patients receive oral placebo once daily. Treatment in both arms continues for 3 years in the absence of progression to prostate cancer or unacceptable toxicity. Patients are followed every 6 months for 2 years and then annually for 8 years. PROJECTED ACCRUAL: A total of 465 patients will be randomized for this study.

Conditions

• Precancerous/Nonmalignant Condition
• Prostate Cancer

Interventions

Type	Name	Description
DRUG	L-selenomethionine	Randomization between active L-selenomethionine and placebo
DRUG	L-selenomethionine placebo	Randomization between active L-selenomethionine and placebo

Timeline

• Start date: 2000-02-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2003-01-27
• Last updated: 2013-02-06
• Results posted: 2013-02-06